Corrigendum to "Home infusion experience in patients with Pompe disease receiving avalglucosidase alfa during three clinical trials" [Molecular Genetics and Metabolism, 143 (2024) 108608]
Mol Genet Metab. 2025 Jan 8;144(3):109006.
doi: 10.1016/j.ymgme.2024.109006.
Online ahead of print.
1 John Walton Muscular Dystrophy Research Centre, Newcastle University International Centre for Life Newcastle upon Tyne, UK. Electronic address: [email protected].
2 Lysosomal Storage Disorders Unit, Royal Free Hospital, London, UK.
3 Department of Neurology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
4 CHU de Lille, Centre de Référence des Maladies Neuromusculaires Nord Est Ile de France, Lille, France.
5 AP-HP, Centre de Référence des Pathologies Neuromusculaires Nord-Est-Ile de France, Service de Neuromyologie, Hôpital de la Pitié-Salpêtrière, Paris, France.
6 Referral Centre for Neuromuscular Diseases, Hôpital Neurologique, Lyon-Bron, France.
7 Great Ormond Street Hospital NHS Foundation Trust, London, UK; National Institute of Health Research Great Ormond Street Hospital Biomedical Research Centre, London, UK.
8 Department of Pediatrics, University of Washington School of Medicine, Seattle Children's Hospital, Seattle, WA, USA.
9 Sanofi, Chilly-Mazarin, France.
10 Sanofi, Amsterdam, the Netherlands.
11 Sanofi, Cambridge, MA, USA.
12 Center for Lysosomal and Metabolic Diseases, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.